CMS should offer more guidance on setting prices for Medicare drugs: Report

A new analysis by the Department of Health and Human Services’ Office of Inspector General found that drugmakers need more guidance from the Centers for Medicare & Medicaid Services on establishing an average sales price that determines reimbursements for Medicare Part B drugs, reports Fierce Healthcare. The review, released Jan. 3, comes amid concerns from physicians that reimbursements for Part B drugs are too low.